Daily Respiratory Research Analysis
Three impactful studies advance respiratory-related science and care: a validated risk score for immune checkpoint inhibitor–associated myocarditis enabling early stratification; a phase 2 trial showing high-dose aumolertinib yields durable systemic and intracranial control in untreated EGFR-variant NSCLC with brain metastases; and mechanistic primate data revealing coordinated lung immune responses that curb Omicron XBB.1.5 replication after prior vaccination/infection.
Summary
Three impactful studies advance respiratory-related science and care: a validated risk score for immune checkpoint inhibitor–associated myocarditis enabling early stratification; a phase 2 trial showing high-dose aumolertinib yields durable systemic and intracranial control in untreated EGFR-variant NSCLC with brain metastases; and mechanistic primate data revealing coordinated lung immune responses that curb Omicron XBB.1.5 replication after prior vaccination/infection.
Research Themes
- Immune checkpoint inhibitor cardiotoxicity risk stratification
- Targeted therapy for EGFR-variant NSCLC with CNS metastases
- Coordinated mucosal immunity against SARS-CoV-2 variants
Selected Articles
1. Immune checkpoint inhibitor-associated myocarditis: a novel risk score.
Using data from 748 patients across 17 countries, the authors derived and externally validated a point-based risk score predicting 30-day severe outcomes in ICI-associated myocarditis. Key predictors included thymoma, cardiomuscular symptoms, low QRS voltage, LVEF <50%, and stepwise troponin elevation; risk rose from 4% (score 0) to 81% (score ≥4). Prospective application identified low-risk patients who safely avoided immunosuppression.
Impact: This externally validated risk tool enables immediate bedside stratification of a life-threatening irAE and may guide immunosuppression intensity and monitoring, including for patients with respiratory muscle failure.
Clinical Implications: Adopt the risk score to triage ICI myocarditis, tailor immunosuppression, and plan monitoring (ECG, troponin, echocardiography), with heightened vigilance for patients with thymoma, low QRS, low LVEF, and high troponin.
Key Findings
- Multicountry registry (n=748) showed 30-day composite severe outcome incidence of 33%, with 13% cardiomyotoxic death.
- Independent predictors: active thymoma, cardiomuscular symptoms, low QRS voltage, LVEF <50%, and graded troponin elevation.
- Risk score stratified outcomes from 4% (score 0) to 81% (score ≥4); externally validated in French and US cohorts.
- Prospective use identified low-risk patients managed without immunosuppression and without cardiomyotoxic events.
Methodological Strengths
- Large multicentre cohort with derivation and external validation across two independent cohorts
- Time-dependent covariates and multiple imputation; transparent Cox modeling with clinically interpretable point score
Limitations
- Retrospective registry design susceptible to residual confounding and ascertainment bias
- Heterogeneity in diagnostics and treatment across 17 countries may affect generalizability
Future Directions: Prospective impact studies to test whether score-guided therapy improves outcomes; integration into EHR for real-time alerts; validation in specific tumor types and across diverse health systems.
BACKGROUND AND AIMS: Immune checkpoint inhibitors (ICI) are associated with life-threatening myocarditis but milder presentations are increasingly recognized. The same autoimmune process that causes ICI myocarditis can manifest concurrent generalized myositis, myasthenia-like syndrome, and respiratory muscle failure. Prognostic factors for this 'cardiomyotoxicity' are lacking. The main aim of this study was to determine predictors and construct a risk score associated with negative outcomes in patients admitted for ICI myocarditis. METHODS: A multicentre registry collected data retrospectively from 17 countries between 2014 and 2023. A multivariable Cox regression model was used to determine risk factors for the primary composite outcome: time to severe arrhythmia, heart failure, respiratory muscle failure, and/or cardiomyotoxicity-related death. Covariates included demographics, comorbidities, cardiomuscular symptoms, diagnostics, and treatments. Time-dependent covariates were used, and missing data were imputed. A point-based prognostic risk score was derived and externally validated. RESULTS: In 748 patients (67% male, age 23-94 years), 30-day incidence of the primary composite outcome, cardiomyotoxic death, and overall death were 33%, 13%, and 17%, respectively. By multivariable analysis, the primary composite outcome was associated with active thymoma (hazard ratio [HR] 3.6, 95% confidence interval [CI] 1.7-7.7), presence of cardiomuscular symptoms (HR 2.6 [1.5-4.2]), low QRS voltage on presenting electrocardiogram (HR for ≤0.5 mV vs >1 mV 1.9 [1.1-3.1]), left ventricular ejection fraction (LVEF) < 50% (HR 1.7 [1.1-2.6]), and incremental troponin elevation (HR 1.8 [1.4-2.4], 2.9 [1.8-4.7], and 4.6 [2.3-9.3], for 20, 200, and 2000-fold above upper reference limit, respectively). A prognostic risk score developed using these parameters showed good performance; 30-day primary outcome incidence increased gradually from 4% (risk score = 0) to 81% (risk score ≥ 4). This risk score was externally validated in two independent French and US cohorts. This risk score was used prospectively in the external French cohort to identify low-risk patients who were managed with no immunosuppression resulting in no cardiomyotoxic events. CONCLUSIONS: ICI-associated myocarditis can manifest with high morbidity and mortality. Myocarditis severity is associated with magnitude of troponin, thymoma, low QRS voltage, depressed LVEF, and cardiomuscular symptoms. A risk score incorporating these features performed well. CLINICAL TRIAL REGISTRATION: NCT04294771 and NCT05454527.
2. Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication.
In rhesus macaques with prior vaccine/infection history, a bivalent WA‑1/BA.5 Novavax boost enhanced cross-reactive S-specific humoral and B-cell responses rather than de novo BA.5 specificity. Upon XBB.1.5 challenge six months later, animals with near-complete control showed robust early trafficking of S-specific IgG, monocytes, B cells, and T cells into the bronchoalveolar space, indicating coordinated local immunity drives protection even when systemic titers change little.
Impact: Defines mucosal cellular and antibody trafficking correlates of cross-variant protection after boosting, informing next-generation mucosal vaccines and correlates beyond serum neutralization.
Clinical Implications: Supports strategies to enhance airway-localized immunity (e.g., mucosal vaccines or adjuvants) and refines immune monitoring to include BAL or mucosal correlates rather than relying solely on serum neutralization.
Key Findings
- Bivalent WA-1/BA.5 Novavax boost primarily increased cross-reactive S-specific antibodies and B cells rather than de novo BA.5-specific responses.
- Six months later, XBB.1.5 reinfection led to low respiratory replication; complete protection aligned with strong influx of S-specific IgG, monocytes, B cells, and T cells into BAL.
- Systemic S-specific immunity changed little, highlighting the importance of coordinated local (mucosal) immunity over serum metrics.
Methodological Strengths
- Stringent heterologous challenge design in primates with well-characterized prior immunity and bivalent boosting
- Integration of humoral, cellular, and compartment-specific (BAL) readouts to link mechanism to protection
Limitations
- Preclinical non-human primate model; sample size and exact group numbers not specified in abstract
- BAL-based correlates may not be readily translatable to routine clinical monitoring
Future Directions: Test intranasal or inhaled vaccine platforms to amplify airway-localized responses; define minimal mucosal correlates for human protection; longitudinal studies linking BAL correlates to breakthrough risk.
Despite waning of virus-neutralizing antibodies, protection against severe SARS-CoV-2 in the majority of immune individuals remains high, but the underlying immune mechanisms are incompletely understood. Here, rhesus macaques with pre-existing immunity from Novavax WA-1 and/or P.1 vaccines and WA-1 or P.1 infection are immunized with a bivalent WA-1/Omicron BA.5 Novavax vaccine ten months after the last exposure. The boost vaccination primarily increases the frequency of cross-reactive spike (S)-specific antibodies and B cells instead of inducing de novo BA.5-specific responses. Reinfection with heterologous Omicron XBB.1.5 six months after the boost vaccination results in low levels of virus replication in the respiratory tract compared with virus-naïve results from other studies. Whereas systemic S-specific immunity remains largely unchanged in all animals, the animals with complete protection from infection exhibit a stronger influx of S-specific IgG, monocytes, B cells and T cells into the bronchioalveolar space combined with expansion of CD69
3. High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.
In untreated EGFR-mutant NSCLC with brain metastases, high-dose aumolertinib (165 mg daily) yielded a 12-month PFS of 62.1%, median PFS of 20.5 months, and intracranial 12-month PFS of 76.8%, with systemic and intracranial ORRs of ~89% and ~83%. Safety was manageable; early plasma ctDNA EGFR variant clearance predicted longer PFS.
Impact: Demonstrates robust systemic and intracranial activity with a CNS-penetrant EGFR-TKI dosing strategy in a high-need population, suggesting a potential frontline option and a biomarker (ctDNA clearance) for response.
Clinical Implications: Consider high-dose aumolertinib as a CNS-active option for untreated EGFR-variant NSCLC with brain metastases; integrate early plasma ctDNA clearance to inform prognosis and treatment adaptation. Randomized comparisons versus standard-dose third-generation EGFR-TKIs are warranted.
Key Findings
- 12-month PFS 62.1% and median PFS 20.5 months in full analysis set; intracranial 12-month PFS 76.8%; OS and intracranial PFS not reached.
- High objective response rates: systemic 88.9% and intracranial 82.5% (RECIST 1.1).
- Grade 3–4 adverse events were manageable, with creatine phosphokinase elevation in 27%; no treatment-related deaths.
- ctDNA EGFR variant clearance by cycle 2 day 1 independently associated with longer PFS (HR 0.14).
Methodological Strengths
- Prospective multicenter phase 2 with prespecified CNS-evaluable set and long follow-up
- Use of RECIST 1.1 for systemic and intracranial responses; incorporation of ctDNA biomarker analysis
Limitations
- Nonrandomized, single-arm design without comparator limits causal inference
- Conducted in one country; generalizability across populations and against other EGFR-TKIs requires RCTs
Future Directions: Randomized trials versus standard-of-care EGFR-TKIs (dose and agent comparisons), CNS pharmacokinetics, and validation of early ctDNA clearance as a decision-making biomarker.
IMPORTANCE: Central nervous system (CNS) metastases remain a significant challenge in the management of EGFR-variant non-small cell lung cancer (NSCLC). OBJECTIVE: To evaluate the activity and safety of high-dose aumolertinib in patients with untreated EGFR-variant NSCLC and brain metastases. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2 nonrandomized clinical trial conducted at 10 centers in China. Patients with untreated EGFR-variant metastatic NSCLC and brain metastases were enrolled between July 6, 2021, and August 31, 2022. The data cutoff date was October 10, 2024. INTERVENTIONS: Patients received aumolertinib, 165 mg, orally once daily until disease progression or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: The primary end point was 12-month progression-free survival (PFS) rate assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1. RESULTS: A total of 63 patients (39 female [61.9%]; median age, 60 [range, 47-76] years) were enrolled (full analysis set), and 49 had at least 1 measurable brain lesion (CNS evaluable-for-response set). Median follow-up duration was 28.8 months (95% CI, 27.0-29.8). In the full analysis set, the 12-month PFS rate was 62.1% (95% CI, 48.7-73.0), the median PFS was 20.5 months (95% CI, 12.0-26.9), the 12-month intracranial PFS rate was 76.8% (95% CI, 63.2-85.9), and the median intracranial PFS and overall survival were not reached. Systemic and intracranial objective response rates per RECIST 1.1 were 56 of 63 (88.9% [95% CI, 78.4-95.4]) and 52 of 63 (82.5% [95% CI, 70.9-90.9]) in the full analysis set and 43 of 49 (87.8% [95% CI, 75.2-95.4]) and 42 of 49 (85.7% [95% CI, 72.8-94.1]) in the CNS evaluable-for-response set, respectively. The most common grade 3 or 4 treatment-related adverse event was increased blood creatine phosphokinase (17 participants [27.0%]). No treatment-related deaths occurred. EGFR variant clearance in plasma circulating tumor DNA at day 1 of cycle 2 was independently associated with longer PFS (hazard ratio, 0.14 [95% CI, 0.04-0.47]; P = .001). CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest that high-dose aumolertinib is associated with long-term survival benefit in patients with untreated EGFR-variant NSCLC and brain metastases, with a manageable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04808752.